Bicycle Therapeutics PLC
BCYC
Company Profile
Business description
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.
Contact
Granta Park, Great Abington
Blocks A and B, Portway Building
CambridgeCB21 6GS
GBRT: +44 1223261503
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
305
Stocks News & Analysis
stocks
Undervalued by 17%, this US cybersecurity leader is a buy for 2026
Here’s a wide-moat company with strong secular tailwinds in a promising industry—and an attractive stock price, too.
stocks
Tough conditions for ASX listed wagering leader
Wagering continues to be challenged in Australia.
stocks
Chart of the Week: Inflation fears dampen sentiment on retailers
Rising inflation is the fly in the ointment.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,045.90 | 27.80 | -0.31% |
| CAC 40 | 8,243.47 | 9.55 | 0.12% |
| DAX 40 | 25,127.46 | 5.20 | 0.02% |
| Dow JONES (US) | 49,266.11 | 270.03 | 0.55% |
| FTSE 100 | 10,044.69 | 3.52 | -0.04% |
| HKSE | 26,232.03 | 82.72 | 0.32% |
| NASDAQ | 23,480.02 | 104.26 | -0.44% |
| Nikkei 225 | 51,939.89 | 822.63 | 1.61% |
| NZX 50 Index | 13,696.25 | 20.61 | -0.15% |
| S&P 500 | 6,921.46 | 0.53 | 0.01% |
| S&P/ASX 200 | 8,717.80 | 29.10 | -0.33% |
| SSE Composite Index | 4,118.40 | 35.42 | 0.87% |